Literature DB >> 4681400

[Behavior of myocardial oxygen consumption in coronary angina induced by exertion and atrial pacing].

G Masini, G Gherardi, R Dianda.   

Abstract

Entities:  

Mesh：

Year:  1972        PMID： 4681400

Source DB:  PubMed          Journal:  Boll Soc Ital Cardiol        ISSN： 0037-878X


× No keyword cloud information.
  14 in total

Review 1.  RAS-targeted therapies: is the undruggable drugged?

Authors:  Amanda R Moore; Scott C Rosenberg; Frank McCormick; Shiva Malek
Journal:  Nat Rev Drug Discov       Date:  2020-06-11       Impact factor: 84.694

Review 2.  Immunotherapy and predictive immunologic profile: the tip of the iceberg.

Authors:  Tatiana Cunha Pereira; Paulo Rodrigues-Santos; Jani Sofia Almeida; Fábio Rêgo Salgueiro; Ana Raquel Monteiro; Filipa Macedo; Rita Félix Soares; Isabel Domingues; Paula Jacinto; Gabriela Sousa
Journal:  Med Oncol       Date:  2021-03-31       Impact factor: 3.064

3.  PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California.

Authors:  Gino K In; Poorva Vaidya; Alexandra Filkins; David J Hermel; Kevin G King; Omar Ragab; William W Tseng; Mark Swanson; Niels Kokot; Julie E Lang; Lawrence Menendez; Brittney DeClerck; Gene Kim; Jenny C Hu; Alicia Terando; Hossein Jadvar; Charité Ricker; Kimberly A Miller; David H Peng; Ashley Wysong
Journal:  J Cancer Res Clin Oncol       Date:  2020-11-18       Impact factor: 4.553

4.  Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition.

Authors:  Rosella Levaggi; Paolo Pertile
Journal:  Appl Health Econ Health Policy       Date:  2020-06       Impact factor: 2.561

Review 5.  Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology.

Authors:  Nicolas A Giraldo; J David Peske; Catherine Sautès-Fridman; Wolf H Fridman
Journal:  Virchows Arch       Date:  2019-01-10       Impact factor: 4.064

6.  Effect of Treatment with the PD-1/PD-L1 Inhibitors on Key Health Outcomes of Cancer Patients.

Authors:  Kyung-In Joung; Jong Hwa Song; Kangho Suh; Seung-Mi Lee; Ji Hyun Jun; Taehwan Park; Dong Churl Suh
Journal:  BioDrugs       Date:  2020-12-17       Impact factor: 5.807

7.  Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors.

Authors:  Pietro Sollena; Vasiliki Nikolaou; Nikolaos Soupos; Elias Kotteas; Dimitra Voudouri; Alexandros J Stratigos; Davide Fattore; Maria Carmela Annunziata; Armando Orlandi; Lucia Di Nardo; Zoe Apalla; Florian Deilhes; Maria Concetta Romano; Gabriella Fabbrocini; Vincent Sibaud; Ketty Peris
Journal:  Breast Cancer Res Treat       Date:  2020-09-10       Impact factor: 4.872

8.  Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.

Authors:  Hisao Imai; Ou Yamaguchi; Hiroyuki Minemura; Kensuke Suzuki; Satoshi Wasamoto; Yukihiro Umeda; Takashi Osaki; Norimitsu Kasahara; Junji Uchino; Tomohide Sugiyama; Shinichi Ishihara; Hisashi Ishii; Ichiro Naruse; Keita Mori; Mie Kotake; Kenya Kanazawa; Koichi Minato; Hiroshi Kagamu; Kyoichi Kaira
Journal:  Cancer Chemother Pharmacol       Date:  2020-03-19       Impact factor: 3.333

9.  Downregulation of the PD-1/PD-Ls pathway in peripheral cells correlates with asbestosis severity.

Authors:  Meihua Qiu; Yuqing Chen; Qiao Ye
Journal:  BMC Pulm Med       Date:  2021-05-22       Impact factor: 3.317

Review 10.  Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC.

Authors:  Michael J Grant; Roy S Herbst; Sarah B Goldberg
Journal:  Nat Rev Clin Oncol       Date:  2021-06-24       Impact factor: 66.675
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.